|Eingestellt in Kategorie:

Führende Biotechnologie-Allianzen: Von Anfang an von Alice M. Sapienza und-

Ursprünglicher Text
Leading Biotechnology Alliances : Right from the Start by Alice M. Sapienza and
pdotwinn
(99)
Angemeldet als privater Verkäufer
Verbraucherschützende Vorschriften, die sich aus dem EU-Verbraucherrecht ergeben, finden daher keine Anwendung. Der eBay-Käuferschutz gilt dennoch für die meisten Käufe. Mehr erfahren
US $14,99
Ca.EUR 12,84
oder Preisvorschlag
Artikelzustand:
Neuwertig
Versand:
US $5,22 (ca. EUR 4,47) USPS Media MailTM.
Standort: Damascus, Maryland, USA
Lieferung:
Lieferung zwischen Fr, 15. Aug und Do, 21. Aug nach 94104 bei heutigem Zahlungseingang
Wir wenden ein spezielles Verfahren zur Einschätzung des Liefertermins an – in diese Schätzung fließen Faktoren wie die Entfernung des Käufers zum Artikelstandort, der gewählte Versandservice, die bisher versandten Artikel des Verkäufers und weitere ein. Insbesondere während saisonaler Spitzenzeiten können die Lieferzeiten abweichen.
Rücknahme:
Keine Rücknahme.
Zahlungen:
   Diners Club 

Sicher einkaufen

eBay-Käuferschutz
Geld zurück, wenn etwas mit diesem Artikel nicht stimmt. Mehr erfahreneBay-Käuferschutz - wird in neuem Fenster oder Tab geöffnet

  • Gratis Rückversand im Inland
  • Punkte für jeden Kauf und Verkauf
  • Exklusive Plus-Deals
Der Verkäufer ist für dieses Angebot verantwortlich.
eBay-Artikelnr.:177110542814

Artikelmerkmale

Artikelzustand
Neuwertig: Buch, das wie neu aussieht, aber bereits gelesen wurde. Der Einband weist keine ...
ISBN
9780471182481

Über dieses Produkt

Product Identifiers

Publisher
Wiley & Sons, Incorporated, John
ISBN-10
0471182486
ISBN-13
9780471182481
eBay Product ID (ePID)
1785145

Product Key Features

Number of Pages
216 Pages
Publication Name
Leading Biotechnology Alliances : Right from the Start
Language
English
Publication Year
2001
Subject
Biotechnology, Industries / Pharmaceutical & Biotechnology, Management
Type
Textbook
Subject Area
Science, Business & Economics
Author
Alice M. Sapienza, Diana Stork
Format
Hardcover

Dimensions

Item Height
0.8 in
Item Weight
16.7 Oz
Item Length
9.3 in
Item Width
6.3 in

Additional Product Features

Intended Audience
Scholarly & Professional
LCCN
2001-017900
Dewey Edition
21
Reviews
"...a discussion of the business of biotechnology..." ( Journal of Proteome Research , Vol. 1, No. 2, March, April 2002)
Illustrated
Yes
Dewey Decimal
660.6/068/1
Table Of Content
TROUBLE IN ALLIANCE LAND. A Case in Point: The Lucida-Pharma Alliance Cast of Characters. The General Case: Many Alliances, Many Problems. ASYMMETRIC RELATIONSHIPS, LOPSIDED RESPONSIBILITY. Contrasting Cultures. Partner Differences and Disparities. LAYING THE GROUNDWORK. Preparing the Organization. Individual and Organizational Due Diligence. The First Meetings. THE ALLIANCE LIFE CYCLE: LEADING DIFFERENTLY OVER TIME. To the First Milestone. Managing Growth and Maturity. Ending: Completion, or Termination. Readiness, Learning, and Alliance Effectiveness: A Road Map. If We Could Turn Back the Clock...(A Hypothetical Coda to the Lucida-Pharma Sciences Case).
Synopsis
Since the early 1990s, research and discovery collaborations between biotechnology and pharmaceutical companies have increased to the point that they now provide more than half of the total capital invested in the biotechnology sector. Although smaller biotechnology companies may be engaged in only a few alliances at a time, some of the most active pharmaceutical players may be engaged in anywhere from thirty to forty alliances at once. Any single alliance relationship may be the lifeblood for a small biotechnology company, while the same relationship may be just one of many for the pharmaceutical partner. Research alliances with small, close-to-the-science companies are the source of many of the innovative ideas of today and the future, but they present formidable challenges. Successful collaboration depends not only on the solution of scientific and technical problems, but also on the successful resolution of many leadership and organizational problems. Leading Biotechnology Alliances presents a tightly focused discussion regarding issues and questions that are unique and critical to the effectiveness of alliances, including: Power differences and other asymmetries between partner firms and some implications for alliance dynamics Sector history and evolution as a basis for understanding the cultural divide that characterizes many biotechnology-pharmaceutical relationships Why leaders on the biotechnology side must assume the greater leadership responsibility in these alliances Different--and predictable--challenges over the alliance life cycle, from start to completion/termination Leadership roles needed for productive and effective collaboration across groups, locations, and companies From societal and economic perspectives, it is important to lead biotechnology alliances right, right from the start. The intent of Leading Biotechnology Alliances is to help scientists and executives from large and small companies do just that--collaborate productively and effectively. This book includes a case study, numerous interview excerpts, general theory and background, a delineation of alliance responsibilities, and a set of alliance effectiveness questions. Together, these ingredients provide the reader with a clear understanding of the complicated dynamics of alliances and leadership issues and roles within the alliance life cycle., Since the early 1990s, research and discovery collaborations between biotechnology and pharmaceutical companies have increased to the point that they now provide more than half of the total capital invested in the biotechnology sector., Fast alle Pharmazie- und Biotechnologieunternehmen bilden strategische Allianzen, die eine gewaltige Herausforderung für das Management bedeuten. "Leading Biotechnology Alliances" vermittelt sofort anwendbare Methoden und Verfahren für den Umgang mit zwischenmenschlichen Beziehungen im Rahmen dieser strategischen Allianzen. Durch die hier vorgestellten "4 Is" der Intergration (Innovation und Kreativität, Ideologie und Kultur, Interdependenz und Konfiguration sowie Individuen und Karriere) schaffen die Autoren einen vorbereiteten Rahmen, der Managern und Wissenschaftlern dabei hilft, die komplexen Fragen im Umgang mit strategischen Allianzen in der täglichen Praxis besser zu verstehen. Enthalten sind Interviews mit einer breiten Palette von Mitarbeitern aus Pharmazie- und Biotechnologieunternehmen. Darüber hinaus behandeln die Autoren auch Fragen, die für Biotechnologie-Allianzen von entscheidender Bedeutung sind. "Leading Biotechnology Alliances" - eine aufschlu reiche Lektüre für Brancheninsider und Investoren gleicherma en., Since the early 1990s, research and discovery collaborations between biotechnology and pharmaceutical companies have increased to the point that they now provide more than half of the total capital invested in the biotechnology sector. Although smaller biotechnology companies may be engaged in only a few alliances at a time, some of the most active pharmaceutical players may be engaged in anywhere from thirty to forty alliances at once. Any single alliance relationship may be the lifeblood for a small biotechnology company, while the same relationship may be just one of many for the pharmaceutical partner. Research alliances with small, close-to-the-science companies are the source of many of the innovative ideas of today and the future, but they present formidable challenges. Successful collaboration depends not only on the solution of scientific and technical problems, but also on the successful resolution of many leadership and organizational problems. Leading Biotechnology Alliances presents a tightly focused discussion regarding issues and questions that are unique and critical to the effectiveness of alliances, including: * Power differences and other asymmetries between partner firms and some implications for alliance dynamics * Sector history and evolution as a basis for understanding the cultural divide that characterizes many biotechnology-pharmaceutical relationships * Why leaders on the biotechnology side must assume the greater leadership responsibility in these alliances * Different - and predictable - challenges over the alliance life cycle, from start to completion/termination * Leadership roles needed for productive and effective collaboration across groups, locations, and companies From societal and economic perspectives, it is important to lead biotechnology alliances right, right from the start. The intent of Leading Biotechnology Alliances is to help scientists and executives from large and small companies do just that - collaborate productively and effectively. This book includes a case study, numerous interview excerpts, general theory and background, a delineation of alliance responsibilities, and a set of alliance effectiveness questions. Together, these ingredients provide the reader with a clear understanding of the complicated dynamics of alliances and leadership issues and roles within the alliance life cycle.
LC Classification Number
HD9999.B442S27 2001
As told to
Lombardino, Joseph G.

Artikelbeschreibung des Verkäufers

Info zu diesem Verkäufer

pdotwinn

100% positive Bewertungen208 Artikel verkauft

Mitglied seit Okt 2013
Antwortet meist innerhalb 1 Stunde
Angemeldet als privater VerkäuferDaher finden verbraucherschützende Vorschriften, die sich aus dem EU-Verbraucherrecht ergeben, keine Anwendung. Der eBay-Käuferschutz gilt dennoch für die meisten Käufe. Mehr erfahrenMehr erfahren

Detaillierte Verkäuferbewertungen

Durchschnitt in den letzten 12 Monaten
Genaue Beschreibung
4.9
Angemessene Versandkosten
4.5
Lieferzeit
5.0
Kommunikation
5.0

Verkäuferbewertungen (68)

Alle Bewertungen
Positiv
Neutral
Negativ